Nicholas G Zaorsky

List of Publications by Year
in descending order

177	6,162	76326	91884
papers	citations	40 h-index	69 g-index

179	179	179	8173
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exposure to radon and heavy particulate pollution and incidence of brain tumors. Neuro-Oncology, 2023, 25, 407-417.	1.2	5
2	Epidemiology of bone metastases. Bone, 2022, 158, 115783.	2.9	61
3	Panâ€cancer analysis of prognostic metastatic phenotypes. International Journal of Cancer, 2022, 150, 132-141.	5.1	19
4	Current treatment and future directions in the management of anal cancer. Ca-A Cancer Journal for Clinicians, 2022, 72, 183-195.	329.8	12
5	Retrospective comparative effectiveness research: will changing the analytical methods change the results?. International Journal of Cancer, 2022, , .	5.1	4
6	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	10.7	68
7	Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes. Clinical Genitourinary Cancer, 2022, , .	1.9	1
8	Non-adherence to multi-modality cancer treatment guidelines in the United States. Advances in Radiation Oncology, 2022, 7, 100938.	1.2	3
9	A Patient-Level Data Meta-analysis of the Abscopal Effect. Advances in Radiation Oncology, 2022, 7, 100909.	1.2	20
10	Demystifying radiation oncology clinical trial concerns for protocol scientific review and institutional review board committee members. Contemporary Clinical Trials Communications, 2022, 27, 100911.	1.1	1
11	Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2022, 86, 1246-1257.	1.2	12
12	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 113, 278-289.	0.8	4
13	Long-Term Risk of Death From Heart Disease Among Breast Cancer Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 784409.	2.4	5
14	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	1.9	19
15	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2022, 40, 2957-2995.	1.6	97
16	Exercise Therapy and Radiation Therapy for Cancer: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 2021, 110, 973-983.	0.8	12
17	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). European Urology, 2021, 80, 280-292.	1.9	140
18	Doseâ€“response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiotherapy and Oncology, 2021, 154, 207-213.	0.6	24

#	Article	IF	Citations
19	Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer. JAMA Oncology, 2021, 7, 92.	7.1	114
20	A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy. Radiotherapy and Oncology, 2021, 155, 188-203.	0.6	37
21	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
22	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanioâ€™s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]. European Urology Focus, 2021, 7, 404-405.	3.1	3
23	Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies. JNCI Cancer Spectrum, 2021, 5, pkab050.	2.9	14
24	Survival after palliative radiation therapy for cancer: The METSSS model. Radiotherapy and Oncology, 2021, 158, 104-111.	0.6	13
25	Sex Differences in Academic Productivity Across Academic Ranks and Specialties in Academic Medicine. JAMA Network Open, 2021, 4, e2112404.	5.9	37
26	Prehabilitation exercise therapy for cancer: A systematic review and metaâ€analysis. Cancer Medicine, 2021, 10, 4195-4205.	2.8	48
27	Authorsâ€™ Reply: To the Letter to the Editor by Kessel et al. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, xliii-xliv.	4.9	0
28	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	8
29	Salvage therapy for prostate cancer after radical prostatectomy. Nature Reviews Urology, 2021, 18, 643-668.	3.8	26
30	Impact of radiation therapy facility volume on survival in patients with cancer. Cancer, 2021, 127, 4081-4090.	4.1	10
31	Potential Winners and Losers: Understanding How the Oncology Care Model May Differentially Affect Hospitals. JCO Oncology Practice, 2021, 17, e1150-e1161.	2.9	0
32	Exercise: A Treatment That Should Be Prescribed With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	0
33	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 572-579.	1.3	15
34	The Epidemiology of Lung Metastases. Frontiers in Medicine, 2021, 8, 723396.	2.6	17
35	Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2021, 111, 371-384.	0.8	18
36	Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the US. JAMA Network Open, 2021, 4, e2127784.	5.9	12

#	Article	IF	Citations
37	Elective Nodal Radiotherapy for Prostate Cancer: For None, Some, or all?. International Journal of Radiation Oncology Biology Physics, 2021, 111, 965-967.	0.8	3
38	Impact of Facility Surgical Volume on Survival in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 495-503.	4.9	10
39	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€"Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Network Open, 2021, 4, e2138550.	5.9	18
40	Gantry-Mounted Linear Acceleratorâ€"Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 404-411.	1.2	6
41	Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. Radiotherapy and Oncology, 2020, 144, 165-179.	0.6	42
42	Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2020, 6, 404-418.	3.1	19
43	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncology, 2020, 6, 1912.	7.1	49
44	Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options. Frontiers in Oncology, 2020, 10, 1616.	2.8	1
45	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiotherapy and Oncology, 2020, 151, 26-32.	0.6	19
46	Publication Productivity and Academic Rank in Medicine: A Systematic Review and Meta-Analysis. Academic Medicine, 2020, 95, 1274-1282.	1.6	43
47	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Radiotherapy and Oncology, 2020, 151, 141-148.	0.6	62
48	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 26-32.	1.2	19
49	Prostate and Pelvis on Pause Pending a Pandemic. International Journal of Radiation Oncology Biology Physics, 2020, 108, 341-342.	0.8	0
50	Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1881.	7.1	66
51	Epidemiology of synchronous brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa041.	0.7	42
52	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e1-848.e7.	1.6	3
53	Epidemiology of liver metastases. Cancer Epidemiology, 2020, 67, 101760.	1.9	120
54	De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials. Oral Oncology, 2020, 103, 104608.	1.5	37

#	Article	IF	Citations
55	Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry. Cancer Medicine, 2020, 9, 3623-3633.	2.8	8
56	Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancerÂ(CRiSP): An international systematic review and metaâ€analysis. Cancer, 2020, 126, 2120-2131.	4.1	72
57	Single fraction radiosurgery, fractionated radiosurgery, and conventional radiotherapy for spinal oligometastasis (SAFFRON): A systematic review and meta-analysis. Radiotherapy and Oncology, 2020, 146, 76-89.	0.6	33
58	Salvage therapy at biochemical recurrence of prostate cancer. Nature Reviews Urology, 2020, 17, 195-196.	3.8	2
59	Reducing the Toxicity of Radiotherapy for Pancreatic Cancer With Magnetic Resonance-guided Radiotherapy. Toxicological Sciences, 2020, 175, 19-23.	3.1	14
60	Fatal heart disease among cancer patients. Nature Communications, 2020, 11, 2011.	12.8	124
61	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy and Oncology, 2020, 148, 235-242.	0.6	33
62	Longâ€term causes of death among pediatric patients with cancer. Cancer, 2020, 126, 3102-3113.	4.1	23
63	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology, 2020, 5, 659-665.	1.2	149
64	Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015. JAMA Network Open, 2020, 3, e2027738.	5.9	91
65	A systematic review of home-based dietary interventions during radiation therapy for cancer. Technical Innovations and Patient Support in Radiation Oncology, 2020, 16, 10-16.	1.9	3
66	Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma. Journal of Thoracic Disease, 2020, 12, 6476-6493.	1.4	0
67	Quantitation and predictors of short-term mortality following extrapleural pneumonectomy, pleurectomy/decortication, and nonoperative management for malignant pleural mesothelioma. Journal of Thoracic Disease, 2020, 12, 6476-6493.	1.4	0
68	Toxicity After Radiotherapy in Patients with Historically Accepted Contraindications to Treatment (CONTRAD): An International Systematic Review and Meta-analysis. International Journal of Radiation Oncology Biology Physics, 2019, 103, E20.	0.8	0
69	The Influence of Online Forums on Radiation Oncology Residency Program Selection. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1009-1011.	0.8	8
70	Surgical excision, Mohs micrographic surgery, externalâ€beam radiotherapy, or brachytherapy for indolent skin cancer: An international metaâ€analysis of 58 studies with 21,000 patients. Cancer, 2019, 125, 3582-3594.	4.1	31
71	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 2019, 5, 958-969.	3.1	86
72	The Decline in Brachytherapy Use for Definitive Cancer Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, E45-E46.	0.8	0

#	Article	IF	Citations
73	Stroke among cancer patients. Nature Communications, 2019, 10, 5172.	12.8	125
74	Riskâ€adapted stereotactic body radiation therapy for central and ultraâ€central earlyâ€stage inoperable nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3553-3564.	3.9	25
75	Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in highâ€risk extremity/trunk softâ€tissue sarcoma?. Cancer, 2019, 125, 3801-3809.	4.1	17
76	Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. European Urology Oncology, 2019, 2, 515-523.	5.4	97
77	Surgical Excision, Mohs Micrographic Surgery, External Beam Radiotherapy, or Brachytherapy for Indolent Skin Cancer: An International Meta-analysis of 58 Studies with 21,000 Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, E34-E35.	0.8	0
78	Long-Term Causes of Death Among Pediatric Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, E16-E17.	0.8	1
79	Single versus Multifraction Stereotactic Radiosurgery for Large Brain Metastases: An International Meta-analysis of 24 Trials. International Journal of Radiation Oncology Biology Physics, 2019, 103, 618-630.	0.8	168
80	Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): An international systematic review and meta-analysis. Radiotherapy and Oncology, 2019, 135, 147-152.	0.6	23
81	Ablative Stereotactic Radiation Therapy for Oligo-metastatic Cancer (ARCH0N): An International Meta-analysis of 19 Prospective Trials. International Journal of Radiation Oncology Biology Physics, 2019, 103, E5-E6.	0.8	0
82	Exceptional Responders in Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 624-635.	1.3	2
83	A population-based study of cardiovascular disease mortality risk in US cancer patients. European Heart Journal, 2019, 40, 3889-3897.	2.2	501
84	Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 46-55.	1.3	26
85	Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiotherapy and Oncology, 2019, 130, 104-112.	0.6	189
86	Industry Funding Is Correlated With Publication Productivity of US Academic Radiation Oncologists. Journal of the American College of Radiology, 2019, 16, 244-251.	1.8	11
87	Suicide among cancer patients. Nature Communications, 2019, 10, 207.	12.8	177
88	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319â€“28. European Urology, 2019, 75, e96-e97.	1.9	1
89	Total skin electron beam therapy in mycosis fungoidesâ€”a shift towards lower dose?. Chinese Clinical Oncology, 2019, 8, 9-9.	1.2	9
90	Clinical Trial Accrual at Initial Course of Therapy for Cancer and Its Impact on Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1309-1316.	4.9	33

#	Article	IF	Citations
91	Google Search Trends in Oncology and the Impact of Celebrity Cancer Awareness. Cureus, 2019, 11, e5360.	0.5	35
92	Genitourinary Cancers. , 2019, , 313-359.		0
93	Adult nodular lymphocyteâ€predominant Hodgkin lymphoma: treatment modality utilization and survival. Cancer Medicine, 2018, 7, 1118-1126.	2.8	9
94	Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis InÂVitro and InÂVivo. International Journal of Radiation Oncology Biology Physics, 2018, 101, 49-62.	0.8	33
95	Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis. Radiotherapy and Oncology, 2018, 126, 386-393.	0.6	35
96	Deviations From Standard Chemoradiation Among Early-Stage Anal Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 100, 945-949.	0.8	1
97	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. Journal of Thoracic Oncology, 2018, 13, 510-520.	1.1	77
98	Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 409-415.	1.3	52
99	Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 116-121.	1.8	11
100	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. International Journal of Molecular Sciences, 2018, 19, 3054.	4.1	44
101	Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines, 2018, 6, 7.	3.2	4
102	Industry Funding Among Leadership in Medical Oncology and Radiation Oncology in 2015. International Journal of Radiation Oncology Biology Physics, 2017, 99, 280-285.	0.8	13
103	Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate, 2017, 77, 1160-1166.	2.3	14
104	ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Advances in Radiation Oncology, 2017, 2, 437-454.	1.2	21
105	Splenic irradiation for splenomegaly: A systematic review. Cancer Treatment Reviews, 2017, 53, 47-52.	7.7	45
106	Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiotherapy and Oncology, 2017, 125, 13-20.	0.6	42
107	(P088) Splenic Irradiation for Splenomegaly: A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 98, E39.	0.8	0
108	(P094) Financial Conflicts of Interest Are Correlated With Publication Productivity Among Academic Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2017, 98, E40-E41.	0.8	0

#	Article	IF	Citations
109	(P077) Hypofractionated Radiation Therapy has Favorable Cosmesis for Indolent Skin Cancers. International Journal of Radiation Oncology Biology Physics, 2017, 98, E36.	0.8	0
110	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	3.8	106
111	(P034) Evolution of Brachytherapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, E24.	0.8	0
112	Causes of death among cancer patients. Annals of Oncology, 2017, 28, 400-407.	1.2	415
113	Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clinical Genitourinary Cancer, 2017, 15, 326-335.e3.	1.9	43
114	ACR Appropriateness Criteria Â® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Advances in Radiation Oncology, 2017, 2, 62-84.	1.2	30
115	Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer. Oncotarget, 2017, 8, 62998-63013.	1.8	5
116	A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Research and Reports in Urology, 2016, Volume 8, 145-158.	1.0	22
117	Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget, 2016, 7, 57391-57413.	1.8	61
118	Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. Journal of Thoracic Disease, 2016, 8, E1028-E1031.	1.4	0
119	97O: Overtreatment of patients with clinically diagnosed early stage lung cancer. Journal of Thoracic Oncology, 2016, 11, S99.	1.1	0
120	Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1112-1120.	1.1	13
121	Pretreatment Predictors of Receiving Adjuvant Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E280.	0.8	0
122	Applying ASTRO APEx Guidelines and RO-ILS to Medical Malpractice in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2016, 96, E540.	0.8	0
123	Dosimetric and Clinical Predictors of Long-Term Toxicity in Patients Undergoing Hypofractionated Prostate Radiation Therapy: Results From a Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, S123.	0.8	1
124	Postmastectomy Radiation Therapy in Women With ypN0-N3 Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, E27.	0.8	0
125	The role of radiation therapy in the management of sialorrhea: A systematic review. Laryngoscope, 2016, 126, 80-85.	2.0	39
126	ASTRO APExÂ®and RO-ILSâ„¢ are applicable to medical malpractice in radiation oncology. Future Oncology, 2016, 12, 2643-2657.	2.4	5

#	Article	IF	Citations
127	Menâ€™s health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. American Journal of Clinical Nutrition, 2016, 104, 1583-1593.	4.7	2
128	The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 321-326.	1.3	7
129	Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treatment Reviews, 2016, 48, 50-60.	7.7	53
130	Importance of Surgical Margin Status in Ductal Carcinoma In Situ. Clinical Breast Cancer, 2016, 16, 312-318.	2.4	8
131	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. Cancer Letters, 2016, 375, 349-359.	7.2	67
132	What Are Medical Students in the United States Learning About Radiation Oncology? Results of a Multi-Institutional Survey. International Journal of Radiation Oncology Biology Physics, 2016, 94, 235-242.	0.8	53
133	Brachytherapy for Prostate Cancer: An Overview. , 2016, , 399-411.		0
134	Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget, 2016, 7, 18135-18145.	1.8	21
135	Patient reported outcomes among treatment modalities for prostate cancer. Canadian Journal of Urology, 2016, 23, 8535-8545.	0.0	15
136	Impact of obesity on outcomes after definitive doseâ€escalated intensityâ€modulated radiotherapy for localized prostate cancer. Cancer, 2015, 121, 3010-3017.	4.1	40
137	Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma. OncoTargets and Therapy, 2015, 8, 437.	2.0	13
138	What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiotherapy and Oncology, 2015, 115, 295-300.	0.6	102
139	Pericytes: a double-edged sword in cancer therapy. Future Oncology, 2015, 11, 169-179.	2.4	61
140	Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy, 2015, 14, 316-321.	0.5	8
141	Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncology, The, 2015, 16, e510-e521.	10.7	160
142	Is robotic arm stereotactic body radiation therapy â€˜virtual high-dose rate brachytherapyâ€™ effective for prostate cancer? An analysis of comparative effectiveness using published data. Expert Review of Medical Devices, 2015, 12, 317-327.	2.8	8
143	Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo. Cancer Letters, 2015, 356, 985-993.	7.2	57
144	Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget, 2015, 6, 15690-15703.	1.8	27

#	Article	IF	Citations
145	Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted". Annals of Translational Medicine, 2015, 3, 274.	1.7	1
146	Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?. Expert Review of Anticancer Therapy, 2014, 14, 39-50.	2.4	14
147	MicroRNA-223 Enhances Radiation Sensitivity of U87MG Cells InÂVitro and InÂVivo by Targeting Ataxia Telangiectasia Mutated. International Journal of Radiation Oncology Biology Physics, 2014, 88, 955-960.	0.8	27
148	High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treatment Reviews, 2014, 40, 414-425.	7.7	57
149	MicroRNA expression altered by diet: Can food be medicinal?. Ageing Research Reviews, 2014, 17, 16-24.	10.9	68
150	Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy, 2014, 13, 456-464.	0.5	6
151	A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncology, 2014, 10, 457-474.	2.4	18
152	Optimizing patient positioning for intensity modulated radiation therapy in hippocampal-sparing whole brain radiation therapy. Practical Radiation Oncology, 2014, 4, 378-383.	2.1	12
153	Chondrosarcoma of the hyoid bone: Case report and review of current management options. Head and Neck, 2014, 36, E65-72.	2.0	14
154	Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. Journal of Thoracic Disease, 2014, 6, 387-98.	1.4	23
155	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro. American Journal of Cancer Research, 2014, 4, 943-51.	1.4	9
156	Image-Guided Focused Ultrasound for the Treatment of Bone Metastases: Current Status and Future Direction. Current Radiology Reports, 2013, 1, 147-153.	1.4	1
157	Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiotherapy and Oncology, 2013, 106, 317-322.	0.6	55
158	Evolution of advanced technologies in prostate cancer radiotherapy. Nature Reviews Urology, 2013, 10, 565-579.	3.8	61
159	The Dilemma of a Rising Prostate-Specific Antigen Level After Local Therapy: What Are Our Options?. Seminars in Oncology, 2013, 40, 322-336.	2.2	36
160	Multimodality Therapy for Patients With High-Risk Prostate Cancer: Current Status and Future Directions. Seminars in Oncology, 2013, 40, 308-321.	2.2	22
161	Impact of a Radiation Oncology Elective on the Careers of Young Physicians: Update on a Prospective Cohort Study. International Journal of Radiation Oncology Biology Physics, 2013, 86, 214-215.	0.8	11
162	Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews, 2013, 39, 728-736.	7.7	56

#	Article	IF	Citations
163	The Responsibilities of a Chief Resident in Radiation Oncology: Results of a National Survey. International Journal of Radiation Oncology Biology Physics, 2013, 87, 460-461.	0.8	5
164	Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?. Cancer Treatment Reviews, 2013, 39, 212-218.	7.7	36
165	Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer Biology and Therapy, 2013, 14, 883-887.	3.4	6
166	Oncology training programs: are we doing comparative effectiveness research justice?. Journal of Comparative Effectiveness Research, 2013, 2, 573-582.	1.4	0
167	ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Nonâ€“Small Cell Lung Cancer Expressing EML4-ALK. Molecular Cancer Therapeutics, 2013, 12, 696-704.	4.1	55
168	Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Review of Medical Devices, 2013, 10, 751-763.	2.8	8
169	SU-E-T-598: Variability of Computer-Generated Organ at Risk Contours as Part of An Automated Deformable Registration Workflow for Prostate Cancer. Medical Physics, 2013, 40, 343-343.	3.0	0
170	The effect of ethnicity and sexual preference on prostate-cancer-related quality of life. Nature Reviews Urology, 2012, 9, 258-265.	3.8	27
171	Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology, 2012, 8, 37-54.	2.4	13
172	A Case of Classic Raymond Syndrome. Case Reports in Neurological Medicine, 2012, 2012, 1-3.	0.4	7
173	Assessing the Value of an Optional Radiation Oncology Clinical Rotation During the Core Clerkships in Medical School. International Journal of Radiation Oncology Biology Physics, 2012, 83, e465-e469.	0.8	28
174	Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, e13-e17.	0.8	37
175	Differentiating Lymphovascular Invasion from Retraction Artifact on Histological Specimen of Breast Carcinoma and Their Implications on Prognosis. Journal of Breast Cancer, 2012, 15, 478.	1.9	17
176	Assessment of the American Joint Committee on Cancer Staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network riskâ€stratification method. Cancer, 2012, 118, 5535-5543.	4.1	25
177	Assessment of the American Joint Committee on Cancer (6th and 7th editions) for clinically localized prostate cancer and comparison to the National Comprehensive Cancer Network risk stratification method.. Journal of Clinical Oncology, 2012, 30, 23-23.	1.6	0